/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Krystal Biotech Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$213.63 0.0112(1.12%) KRYS at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 215.94
Highest Today 219.02
Today’s Open 217.17
Prev. Close 215.06
52 Week High 221.84
52 Week Low 122.80
Day’s Range: Low 215.94 High 219.02
52-Week Range: Low 122.80 High 221.84
1 day return -
1 Week return -0.01
1 month return +7.21
3 month return +45.75
6 month return +65.08
1 year return +16.16
3 year return +187.59
5 year return +286.29
10 year return -

Institutional Holdings

FMR Inc 14.98

BlackRock Inc 13.29

Vanguard Group Inc 9.75

venBio Select Advisor LLC 9.19

Fidelity Select Biotechnology 6.41

iShares Core S&P Small-Cap ETF 5.23

State Street Corp 4.68

Fidelity Growth Compy Commingled Pl S 3.33

Capital World Investors 3.26

Soleus Capital Management, L.P. 3.19

American Funds SMALLCAP World A 3.06

Vanguard Total Stock Mkt Idx Inv 2.83

BRAIDWELL LP 2.51

Fidelity Growth Company Fund 2.43

Redmile Group, LLC 2.29

Vanguard Small Cap Index 2.18

Geode Capital Management, LLC 2.14

iShares Russell 2000 ETF 2.06

Hood River Capital Management LLC 1.84

Goldman Sachs Group Inc 1.83

Dimensional Fund Advisors, Inc. 1.75

SPDR® S&P Biotech ETF 1.46

Vanguard Small Cap Growth Index Inv 1.23

Hood River Small-Cap Growth Instl 1.00

NORGES BANK 0.98

Vanguard Institutional Extnd Mkt Idx Tr 0.94

T. Rowe Price Associates, Inc. 0.90

Northern Trust Corp 0.87

Fidelity Small Cap Index 0.86

Charles Schwab Investment Management Inc 0.85

Morgan Stanley - Brokerage Accounts 0.81

UBS Asset Mgmt Americas Inc 0.81

First Trust NYSE Arca Biotech ETF 0.79

SPDR® Portfolio S&P 600™ Sm Cap ETF 0.78

First Trust Advisors L.P. 0.77

iShares S&P Small-Cap 600 Growth ETF 0.76

Fidelity Growth Company K6 0.76

iShares Russell 2000 Growth ETF 0.75

Fidelity Series Growth Company 0.64

Vanguard Tax-Managed Small Cap Adm 0.56

Market Status

Strong Buy: 8

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 6236.21 M

PB Ratio 5.5555

PE Ratio 32.2429

Enterprise Value 5599.90 M

Total Assets 1055.84 M

Volume 240262

Company Financials

Annual Revenue FY24:290515000 290.5M, FY23:50699000 50.7M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:270454000 270.5M, FY23:42598000 42.6M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:89159000 89.2M, FY23:10932000 10.9M, FY22:-139975000 -140.0M, FY21:-69570000 -69.6M, FY20:-32167000 -32.2M

Quarterly Revenue Q3/2025:97800000 97.8M, Q2/2025:96042000 96.0M, Q1/2025:88183000 88.2M, Q4/2024:91139000 91.1M, Q3/2024:83841000 83.8M

Quarterly Profit Q3/2025:92137000 92.1M, Q2/2025:88877000 88.9M, Q1/2025:83155000 83.2M, Q4/2024:86190000 86.2M, Q3/2024:77157000 77.2M

Quarterly Net worth Q3/2025:79365000 79.4M, Q2/2025:38333000 38.3M, Q1/2025:35733000 35.7M, Q4/2024:45479000 45.5M, Q3/2024:27180000 27.2M

Fund house & investment objective

Company Information Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Organisation Biotechnology

Employees 275

Industry Biotechnology

CEO Mr. Krish S. Krishnan M.B.A., M.S.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow